Biocon Ltd Rights

Biocon gets six-month extension on insulin supply pact

 Copy Link

In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.

Biocon shares zoom ~2% after drug launch in Japan

 Copy Link

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

Biocon Q4 Net Profit Soars 154% YoY to ₹344.5 Crore

 Copy Link

The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.

Biocon Biologics Secures Multiple Market Access for Yesintek

 Copy Link

Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.

Biocon to Raise ₹4,500 Crore; Approves Capital Expansion Plan

 Copy Link

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

Top Stocks for Today - 24th April 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.

Biocon unit expands oncology portfolio after USFDA approval

 Copy Link

Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.

Biocon Pharma Gains USFDA Approval for Norepinephrine and Key Therapies

 Copy Link

The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.

Biocon Biologics inks pact with Civica to expand access in US

 Copy Link

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

Biocon Secures USFDA Approval for Dasatinib

 Copy Link

The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.